Clinical trial
Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis…
NCT00481962 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00481962 |
|---|---|
| Title | Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units (ICUs) |
| Official title | Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Peritonitis |
| Intervention type | Drug |
| Interventions | Tygacil |
| Enrollment | 180 |
| Start date | Feb 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Jun 4, 2007 |
| Last update posted | Sep 28, 2009 |
| Countries | Germany |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: